| | | | | Präparat | Packungsgrösse | EFP | PP | SB | TK | Zusammensetzung | Zulassungsinhaber | Kat. | | | | |
---|
|
L | | FI | PI | | Sunitinib Viatris 12.5 mg | 28 | 800.81 | 887.35 | 10% | | Kapseln: Sunitinibum 12.5 mg | Viatris Pharma GmbH | A / SL / SG | FB | | G |  |
L | | FI | | | Sunitinib Viatris 25 mg | 28 | 1601.50 | 1758.15 | 10% | | Kapseln: Sunitinibum 25 mg | Viatris Pharma GmbH | A / SL / SG | FB | | G |  |
L | | FI | | | Sunitinib Viatris 50 mg | 28 | 3046.34 | 3329.50 | 10% | | Kapseln: Sunitinibum 50 mg | Viatris Pharma GmbH | A / SL / SG | FB | | G |  |
L | KFI | FI | PI | | Sutent 12.5 mg | 28 Kapsel(n) | 880.89 | 969.50 | 10% | | Kapseln: Sunitinibum 12.5 mg | Pfizer AG | A / SL / SO | FB | | G |  |
L | KFI | FI | PI | | Sutent 25 mg | 28 Kapsel(n) | 1761.64 | 1922.45 | 10% | | Kapseln: Sunitinibum 25 mg | Pfizer AG | A / SL / SO | FB | | G |  |
L | KFI | FI | PI | | Sutent 50 mg | 28 Kapsel(n) | 3350.97 | 3642.05 | 10% | | Kapseln: Sunitinibum 50 mg | Pfizer AG | A / SL / SO | FB | | G |  |
L | | FI | PI | | Sunitinib Zentiva 12.5 mg | 28 | 800.81 | 887.35 | 10% | | Kapseln: Sunitinibum 12.5 mg | Helvepharm AG | A / SL / SG | FB | | G |  |
L | | FI | | | Sunitinib Zentiva 25 mg | 28 | 1601.50 | 1758.15 | 10% | | Kapseln: Sunitinibum 25 mg | Helvepharm AG | A / SL / SG | FB | | G |  |
L | | FI | | | Sunitinib Zentiva 50 mg | 28 | 3046.34 | 3329.50 | 10% | | Kapseln: Sunitinibum 50 mg | Helvepharm AG | A / SL / SG | FB | | G |  |
L | | FI | PI | | Sunitinib-Teva 12.5 mg | 28 | 800.81 | 887.35 | 10% | | Kapseln: Sunitinibum 12.5 mg | Teva Pharma AG | A / SL / SG | FB | | G |  |
L | | FI | | | Sunitinib-Teva 25 mg | 28 | 1601.50 | 1758.15 | 10% | | Kapseln: Sunitinibum 25 mg | Teva Pharma AG | ● A / SL / SG | FB | | G |  |
L | | FI | | | Sunitinib-Teva 50 mg | 28 | 3046.34 | 3329.50 | 10% | | Kapseln: Sunitinibum 50 mg | Teva Pharma AG | A / SL / SG | FB | | G |  |
|
L | KFI | FI | PI | | Nexavar | 112 Tablette(n) | 2869.05 | 3112.40 | 10% | | Filmtabletten: Sorafenibum 200 mg | Bayer (Schweiz) AG | A / SL / SO | FB | | G |  |
L | | FI | PI | | Sorafenib Zentiva 200 mg | 112 | 2474.29 | 2707.35 | 10% | | Filmtabletten: Sorafenibum 200 mg | Helvepharm AG | A / SL / SG | FB | | G |  |
|
| | | | | Pazopanib Spirig HC 200 mg | 30 | PA | PA | k.A. | | Filmtabletten: Pazopanibum 200 mg | Spirig HealthCare AG | A | FB | | G |  |
| | | | | Pazopanib Spirig HC 400 mg | 60 | PA | PA | k.A. | | Filmtabletten: Pazopanibum 400 mg | Spirig HealthCare AG | A | FB | | G |  |
|
L | | FI | PI | PS | Caprelsa 100 mg | 30 Tablette(n) | 2126.12 | 2328.70 | 10% | | Filmtabletten: Vandetanibum 100 mg | Sanofi-Aventis (Suisse) SA | A / SL | FB | | G |  |
L | | FI | PI | PS | Caprelsa 300 mg | 30 Tablette(n) | 4497.43 | 4907.65 | 10% | | Filmtabletten: Vandetanibum 300 mg | Sanofi-Aventis (Suisse) SA | A / SL | FB | | G |  |
|
L | | FI | PI | PS | Stivarga 40 mg | 3 x 28 Tablette(n) | 2963.85 | 3239.80 | 10% | | Filmtabletten: Regorafenibum 40 mg | Bayer (Schweiz) AG | A / SL | FB | | G |  |
|
L | | FI | | PS | Cabometyx 60 mg | 30 | 4670.20 | 5095.55 | 10% | | Filmtabletten: 2 Wirkstoffe | Ipsen Pharma Schweiz GmbH | A / SL | FB | | G |  |
L | | FI | PI | PS | Cabometyx 20 mg | 30 | 4670.20 | 5095.55 | 10% | | Filmtabletten: Cabozantinibum 20 mg | Ipsen Pharma Schweiz GmbH | A / SL | FB | | G |  |
L | | FI | | PS | Cabometyx 40 mg | 30 | 4670.20 | 5095.55 | 10% | | Filmtabletten: Cabozantinibum 40 mg | Ipsen Pharma Schweiz GmbH | A / SL | FB | | G |  |
|
L | | FI | PI | PS | Lenvima 4 mg | 30 Kapsel(n) | 1482.50 | 1628.70 | 10% | | Kapseln: Lenvatinibum 4 mg | Eisai Pharma AG | A / SL | FB | | G |  |
L | | FI | PI | PS | Lenvima 10 mg | 30 Kapsel(n) | 1482.50 | 1628.70 | 10% | | Kapseln: Lenvatinibum 10 mg | Eisai Pharma AG | A / SL | FB | | G |  |
| | FI | PI | | Kisplyx 4 mg | 30 | PA | PA | k.A. | | Kapseln: Lenvatinibum 4 mg | Eisai Pharma AG | A | FB | | G |  |
| | FI | PI | | Kisplyx 10 mg | 30 | PA | PA | k.A. | | Kapseln: Lenvatinibum 10 mg | Eisai Pharma AG | A | FB | | G |  |
|
L | | FI | PI | PS | OFEV 100 mg | 60 Kapsel(n) | 1988.75 | 2179.30 | 10% | | Weichkapseln: Nintedanibum 100 mg | Boehringer Ingelheim (Schweiz) GmbH | B / SL | FB | | G |  |
L | | FI | PI | PS | OFEV 150 mg | 60 Kapsel(n) | 1988.75 | 2179.30 | 10% | | Weichkapseln: Nintedanibum 150 mg | Boehringer Ingelheim (Schweiz) GmbH | B / SL | FB | | G |  |
|
| | FI | PI | PS | Rydapt 25 mg | 56 | PA | PA | k.A. | | Weichkapseln: Midostaurinum 25 mg | Novartis Pharma Schweiz AG | A | FB | | G |  |
| | FI | PI | PS | Rydapt 25 mg | 112 | PA | PA | k.A. | | Weichkapseln: Midostaurinum 25 mg | Novartis Pharma Schweiz AG | A | FB | | G |  |
|
| | FI | PI | | VANFLYTA 17.7 mg | 14 | PA | PA | k.A. | | Filmtabletten: Quizartinibi Dihydrochloridum 20 mg | Daiichi Sankyo (Schweiz) AG | A | FB | | G |  |
| | FI | PI | | VANFLYTA 17.7 mg | 28 | PA | PA | k.A. | | Filmtabletten: Quizartinibi Dihydrochloridum 20 mg | Daiichi Sankyo (Schweiz) AG | A | FB | | G |  |
| | FI | | | VANFLYTA 26.5 mg | 14 | PA | PA | k.A. | | Filmtabletten: Quizartinibi Dihydrochloridum 30 mg | Daiichi Sankyo (Schweiz) AG | A | FB | | G |  |
| | FI | | | VANFLYTA 26.5 mg | 28 | PA | PA | k.A. | | Filmtabletten: Quizartinibi Dihydrochloridum 30 mg | Daiichi Sankyo (Schweiz) AG | A | FB | | G |  |
| | FI | | | VANFLYTA 26.5 mg | 56 | PA | PA | k.A. | | Filmtabletten: Quizartinibi Dihydrochloridum 30 mg | Daiichi Sankyo (Schweiz) AG | A | FB | | G |  |
|
L | | FI | PI | | Vitrakvi 25 mg | 56 | 1351.24 | 1485.95 | 10% | | Kapseln: Larotrectinibum 25 mg | Bayer (Schweiz) AG | A / SL | FB | | G |  |
L | | FI | | | Vitrakvi 100 mg | 56 | 5422.83 | 5871.60 | 10% | | Kapseln: Larotrectinibum 100 mg | Bayer (Schweiz) AG | A / SL | FB | | G |  |
L | | FI | PI | | Vitrakvi 20 mg/ml | 100 ml | 1932.71 | 2118.35 | 10% | | Lösung (oral): Larotrectinibum 20 mg/ml | Bayer (Schweiz) AG | A / SL | FB | | G |  |
|
L | | FI | PI | | Xospata 40 mg | 84 | 15062.96 | 15762.40 | 10% | | Filmtabletten: Gilteritinibum 40 mg | Astellas Pharma AG | A / SL | FB | | G |  |
|
L | | FI | PI | | Rozlytrek 100 mg | 30 | 817.78 | 905.80 | 10% | | Kapseln: Entrectinibum 100 mg | Roche Pharma (Schweiz) AG | A / SL | FB | | G |  |
L | | FI | | | Rozlytrek 200 mg | 90 | 4906.67 | 5342.05 | 10% | | Kapseln: Entrectinibum 200 mg | Roche Pharma (Schweiz) AG | A / SL | FB | | G |  |
|
L | | FI | PI | | Tabrecta 150 mg | 120 | 5503.34 | 5954.25 | 10% | | Filmtabletten: Capmatinibum 150 mg | Novartis Pharma Schweiz AG | A / SL | FB | | G |  |
L | | FI | | | Tabrecta 200 mg | 120 | 5503.34 | 5954.25 | 10% | | Filmtabletten: Capmatinibum 200 mg | Novartis Pharma Schweiz AG | A / SL | FB | | G |  |
|
| | FI | PI | | Ayvakyt 25 mg | 30 | PA | PA | k.A. | | Filmtabletten: Avapritinibum 25 mg | Blueprint Medicines (Switzerland) GmbH | A | FB | | G |  |
| | FI | | | Ayvakyt 50 mg | 30 | PA | PA | k.A. | | Filmtabletten: Avapritinibum 50 mg | Blueprint Medicines (Switzerland) GmbH | A | FB | | G |  |
| | FI | | | Ayvakyt 100 mg | 30 | PA | PA | k.A. | | Filmtabletten: Avapritinibum 100 mg | Blueprint Medicines (Switzerland) GmbH | A | FB | | G |  |
| | FI | | | Ayvakyt 200 mg | 30 | PA | PA | k.A. | | Filmtabletten: Avapritinibum 200 mg | Blueprint Medicines (Switzerland) GmbH | A | FB | | G |  |
| | FI | | | Ayvakyt 300 mg | 30 | PA | PA | k.A. | | Filmtabletten: Avapritinibum 300 mg | Blueprint Medicines (Switzerland) GmbH | A | FB | | G |  |
|
L | | FI | PI | | Qinlock 50 mg | 90 | 19135.37 | 19940.70 | 10% | | Tabletten: Ripretinibum 50 mg | Deciphera Pharmaceuticals (Schweiz) AG | A / SL | FB | | G |  |
|
L | | FI | PI | | Tepmetko 225 mg | 60 | 5981.89 | 6445.20 | 10% | | Filmtabletten: Tepotinibum 225 mg | Merck (Schweiz) AG | A / SL | FB | | G |  |
|
L | | FI | PI | | Retsevmo 40 mg | 56 | 1958.87 | 2146.80 | 10% | | Kapseln: Selpercatinibum 40 mg | Eli Lilly (Suisse) SA | A / SL | FB | | G |  |
L | | FI | | | Retsevmo 80 mg | 56 | 3917.73 | 4277.20 | 10% | | Kapseln: Selpercatinibum 80 mg | Eli Lilly (Suisse) SA | A / SL | FB | | G |  |
| | FI | | | Retsevmo 80 mg | 112 | PA | PA | k.A. | | Kapseln: Selpercatinibum 80 mg | Eli Lilly (Suisse) SA | A | FB | | G |  |